

INDEX

Note: Page numbers in *italics* indicate figures;
page numbers followed by t refer to tables.

- Abdominal examination, in heart failure diagnosis, 73t, 74
ACC/AHA. See *American College of Cardiology/American Heart Association*.
ACCLAIM, 98t, 100t, 32t
Accupril (quinapril), 188t
ACE inhibitors. See *Angiotensin-converting enzyme inhibitors*.
Acebutolol, 196t
Acetazolamide, 175, 176t
Achromycin V (tetracycline), 212
Acidosis, 177t, 226t, 227
Acorn cardiac support, 297, 306
Acrocyanosis, 74
Acromegaly, 32t, 35
Actin-myosin interaction, 41, 43-44
ACTION, guidelines on heart failure treatment, 316t
Actose (pioglitazone), 134, 135t, 217, 230t
Acute heart failure, 22t-23t
Acute ischemic syndromes, 20
 in acute vs chronic heart failure, 23t
Addison's disease, 35
Adenosine triphosphate, cross-bridge formation and, 44
Adenovirus, 31t, 35
ADHERE database, 227-228
ADOPT-A, 274t, 32t
Adrenal cortical insufficiency, 32t
Adrenal gland, cardiac output and, 52
Adrenergic blockers. See *α-Blockers*; *β-Blockers*.
Adrenergic receptors, density of, 45, 48
AFFIRM, 271
AFT, 274t, 32t
Afterload
 definition of, 53, 55
 tricyclic antidepressants and, 136
Age, heart failure death and, 21, 26, 26t, 143, 144
 future projections of, 27
AIRE, 95, 96t, 99, 186, 321
AIREX, 95, 96t, 100t, 32t
Airflow limitations, 90t
Alcohol intake, 33t, 36, 42, 139, 142
 cardiac transplantation and, 310t
 heart failure treatment and, 65, 156t
 myocardial injury and, 46t
Aldactone. See *Spironolactone*.
Aldosterone
 left ventricular fibrosis and remodeling and, 57
 renal effects of, 57, 58t
Aldosterone antagonists. See also *Eplerenone*; *Spironolactone*.
 in ACC/AHA heart failure management guidelines, 65
 endocrinopathy and, 18t
 hyperkalemia and, 79
 indications for, 19, 177, 181, 218t
Alkalosis, 81
ALLHAT, 97t, 100t, 32t
Allopurinol, 218t
α-Adrenergic receptor density, 45, 48
α-Blockers
 adverse effects of, 205, 206t-207t
 clinical trials of, 97t, 100t
 dosage of, 206t-207t
 indications for, 45, 48, 164
Altace. See *Ramipril*.
Altitude, 229, 230t
Alveolar disease, 90t
American College of Cardiology/American Heart Association
 classification of heart failure by, 64, 65
 clinical history and, 69
 treatment strategy and, 131, 132-133
American College of Cardiology/American Heart Association (*continued*)
 guidelines of
 on heart failure treatment, 65, 316t, 317t
 on inotrope infusion, 252, 256
Amiloride (Midamor), 171t
Amiodarone (Cordarone)
 adverse effects of, 199, 203, 205t, 268-269
 for atrial fibrillation, 199, 268, 270, 271t
 bradycardia and, 199, 201t
 clinical trials of, 96t, 100t-104t, 106t-108t, 111t, 114t, 123-124, 282t, 321-322.
 See also *AMIOVERT*; *CAMIAT*; *EMIAAT*.
 decompensated heart failure and, 230t
 digoxin and, 203, 205t
 indications for, 159, 268
 preventive, 124, 280, 282t
 safety of, 268-269
 thyroid function and, 81
 warfarin interaction with, 212
AMIOVERT, 96t-97t, 100t, 32t. See also *Amiodarone, clinical trials of*.
Amlodipine (Norvasc)
 adverse effects of, 134, 203
 clinical trials of, 97t, 100t, 111t, 127, 129. See also *PRAISE*.
 dosage of, 207t
 for hypertension, 164, 167
Amrinone
 adverse effects of, 244t
 parenteral, hemodynamic effects of, 242t
Amyloidosis, 31t-32t, 35
Anaphylaxis, 170t
Anemia, 32t, 35, 79
 decompensated heart failure and, 230t
 exercise intolerance in, 90t
Aneurysm, aortic dissection and, 37t
Aneurysmectomy, left ventricular, 156t, 251, 252t
Angina
 biventricular pacing in. See *COMPANION*; *MIRACLE* entries; *SCD-HeFT*.
 drug selection in, 164
 dyspnea and, 167
 revascularization for, 144, 164, 167
 unstable, 37t
Angiotensin. See also *Renin-angiotensin-aldosterone system*.
Angiotensin I, conversion to angiotensin II, 57, 59
Angiotensin II
 cardiac output and, 52
 myocardial hypertrophy and, 45
 renal effects of, 58t
 vasoconstriction and, 54
 vasodilation and, 53
Angiotensin II receptor blockers (ARBs)
 in ACC/AHA guidelines, 65, 132
 ACE inhibitors with, 57, 137, 166, 190t, 201, 203
 adverse effects of, 190t, 206t
 brain natriuretic peptide level and, 217
 clinical trials of, 96t, 114t-118t, 125-126, 137, 199, 201, 203
 in congestive heart failure, 96t
 discontinuation of, 139
 dosage of, 206t, 217, 224t, 230t
 for dyspnea, 164, 167
 effectiveness of, 137, 201, 203
 endocrinopathy and, 18t
 hyperkalemia and, 79
 for hypertension, 167
 indications for, 45, 48, 128, 135t-136t, 136t, 159, 162-163, 166, 189, 217, 318t
 after myocardial infarction, 96t
 in polypharmacologic treatment, 57, 137-138, 161, 189, 201, 205
 preventive, 159
Angiotensin-converting enzyme (ACE), angiotensin I conversion by, 57, 59
Angiotensin-converting enzyme (ACE) inhibitors. See also *APRES*; *CONSENSUS*;
 FACET; *FIRST*; *RADIANCE*; *SOLVD*; specific drugs; *V-HeFT*.
 in ACC/AHA guidelines, 65, 132
 adverse effects of, 184, 187, 189, 1920t
 ARBs with, 57, 137, 166, 190t, 201, 203

Angiotensin-converting enzyme (ACE) inhibitors (*continued*)

β-blockers with, 136, 137-138, 191, 198-199, 200t, 215-216
clinical trials of, 94-95, 96t, 99, 100t-101t, 103t-109t, 111t-117t, 119, 120, 126-127, 129, 168, 184-187
in congestive heart failure, 96t
cough and, 125, 128, 189, 190t
daily protocol for, 220, 220t
diabetes and, 155t
diuretics with, 138, 171t, 182t, 190t, 215, 236
dosage of, 138, 162-163, 166, 186-187, 230t
decreased, 221, 223-224
inadequate, 156t-157t, 157, 230t
effectiveness of, 128, 137, 183-184, 184-187, 201
endocrinopathy and, 18t, 19
eplerenone with, 127
guidelines for use of, 65, 132, 315, 318t
hydralazine with, 203, 205
hyperkalemia and, 79, 189, 190t
hypotension and, 189, 190t
indications for, 135t-136t, 159t, 165, 180, 183-184, 198, 217, 218t, 315, 318t
after infarct exclusion surgery, 305t
intolerance of, studies of, 115t. See also *SPICE*.
for left ventricular systolic dysfunction, 166, 183
mortality end points with, 184-187
neutral endopeptidase inhibitor with, 99
peripheral vascular disease and, 155t
in polypharmacy, 161, 213, 215
preventive, 159
renal function and, 189, 190t
timing of, 198-199, 220
for volume overload, 161, 162-163, 166

Anoxia, 30

Antabuse (disulfiram), 212

Anthracyclines, 30, 33t, 36, 42
necrosis and apoptosis from, 45, 46t
as therapeutic pitfall, 157t

Antiarrhythmics
adverse effects of, 134, 135t, 151-152, 154, 157t, 167, 216-217, 258t
for atrial fibrillation, 267, 270, 271t, 279
after cardiac arrest, 287
clinical trials of, 96t, 101t, 103t-105t, 115t-116t, 123-125, 128. See also *AVID*; *BASIS*;
CAST; *CHF-STAT*.
electrical cardioversion and, 271
implanted. See *Cardioversion defibrillators, implanted*.
for tachycardia, 288
Vaughn-Williams class I, 103t, 267

Anticoagulants, 136
algorithm for, 209-212
for atrial fibrillation, 165
before cardioversion, 266
clinical trial of, 98t, 117t
controversy over, 136-137
discontinuation of, 135t
dosage of, 211
drug interactions with, 208, 212
indications for, 205, 208
patient self-monitoring and, 208

Antidepressants, tricyclic, 135t, 136

Antidiuretic hormone, 56, 57. See also *Arginine vasopressin*.

Antihistamines, 135t

Anti-inflammatory drugs. See also *Aspirin*; *Nonsteroidal Anti-inflammatory drugs*.
cytokines as, 62
indications for, 17

Antiplatelet agents, 218t

Anturane (sulfapyrazone), 212

Aortic aneurysm, rupture of, 151

Aortic dissection, 37t

Aortic regurgitation, flash pulmonary edema and, 20

Aortic stenosis, 46t

Aortic valve, acute catastrophe of, 230t

Aortic valve insufficiency
hemodynamic patterns in, 240t
in low cardiac output, 25t
pathophysiology of, 37t
in volume overload, 42, 46t

Aortic valve repair/replacement
indications for, 299-300
for refractory heart failure, 250-251, 252t

Apnea, in sleep, 154, 219
in COPD, 155t
in decompensated heart failure, 225, 226t, 230t
management of, 218t, 219
right heart failure and, 71

Apoptosis
causes of, 45, 46t
myocytic, necrosis vs, 47, 49t
premature, 64t

APRES, 96t, 101t, 321. See also *Amiodarone, clinical trials of*.

Apresoline. See *Hydralazine*.

Aquaresis, 52

ARBs. See *Angiotensin II receptor blockers*.

Arginine vasopressin
cardiac output and, 52, 53, 54
ejection fraction and, 56, 57
myocardial hypertrophy and, 45, 47t
renal effects of, 57, 58t, 60, 61
vasoconstriction and, 54
vasodilation and, 53

Arrhythmia. See also *Antiarrhythmics*; *Atrial arrhythmia*; *Atrial fibrillation*; *Death from heart failure, sudden*; *Ventricular arrhythmia*.
causes of, 152
in decompensated heart failure, 226t, 227, 230t
drug-induced, 134, 135t, 152, 244t
electrophysiologic considerations in, 258t
electrophysiologic studies in, indications for, 285t, 287-289;
frequency of, 149
malignant ventricular, 123
management of
cardioversion in, 266-267, 271. See also *Cardioversion defibrillators*.
controversies in, 258t
in muscular dystrophy, 29, 33t
prevalence of, 258t
screening for, 258t
trials of, 123-125
undiagnosed/untreated, 157t

Arterial blood gases, 80t, 81

Arterial pressure
contractility and, 53, 55
mean, in parenteral drug therapy, 242t-243t

Arteriovenous fistula, peripheral, 37t

Ascites, 225

ASPECT, 274t, 321

Aspirin. See also *Nonsteroidal anti-inflammatory drugs*.
for angina, 164, 167
daily protocol for, 220t
indications for, 155t, 164-165, 219

AT500, 274t

Atacand. See *Candesartan*.

Atenolol, 193, 196t

Atherosclerosis, heart disease from
evaluation of, 145
frequency of, 143

ATLAS, 96t, 101t, 321. See also *Lisinopril, clinical trials of*.

Atrial arrhythmia
in decompensated heart failure, 226t, 227
sustained, 37t

Atrial biventricular pacing, 109t

Atrial defibrillation. See also *Cardioversion defibrillation*.

Atrial enlargement, 208

Atrial fibrillation, 72. See also *Arrhythmia*.
cardioversion therapy failure in, 279
catheter-based ablation for, 272-273, 276t-278t

- Atrial fibrillation (*continued*)
 chronic, 153
 classification of, 267t
 clinical studies of, 111t. See also *PIAF*.
 clinical trials of, 271-273
 conditions predisposing to, 269t
 decompensated heart failure and, 230t
 early conversion of, 271-272
 incidence of, 261, 268
 management of, 165, 167-168, 218t, 219, 266
 algorithm for, 270
 Maze procedure for, 272, 295
 newly detected, 319t
 pacing for, 272, 274t-275t
 physiologic effects of, 258t, 261, 266
 prognosis and, 143
 surgery for, 272
 undiagnosed/untreated, 157t
- Atrial natriuretic peptide
 ejection fraction and, 51, 54
 remodeling and, 47t
 renal effects of, 58t, 60
 source of, 61t
- Atrial pressure, in decompensation, 240t
- Atrial-ventricular nodal blockade, 269
- Atrial-ventricular synchrony, 153, 153t
- ATTEST, 274t, 321
- A-type natriuretic peptide. See *Atrial natriuretic peptide*.
- Autoimmune myocarditis, 31t
- Autoregulation of cardiac output, 53, 54
- Avandia (rosiglitazone)
 adverse effects of, 134, 157, 216-217, 230t
 discontinuation of, 135t
- Avapro (irbesartan), 206t
- AVID, 101t, 280, 282t, 321. See also *Antiarrhythmics, clinical trials of; Cardioversion defibrillators, implanted*.
- Avocado, 212
- Azathioprine (Imuran)
 clinical trials of, 110t
 warfarin interaction with, 212
- Azotemia, 157t
 causes of, 221, 224
 in decompensation, 234t
 prerenal, 81
 in decompensated heart failure, 226t, 227
- Bacterial endocarditis, 31t, 35
- Balke exercise test, 86, 88
- Barbiturates, 212
- Baroreceptor, 55
 cardiac output and, 52
- BASIS, 96t, 101t, 321. See also *Antiarrhythmics, clinical trials of*.
- Batista procedure, 252t, 300-301
- Becker muscular dystrophy, 33t, 36
- Bedrest, 139-140
- Benazepril (Lotensin), 186t
- Benicar (olmesartan), 206t
- Berberi, 32t, 35
- BEST, 97t, 101t, 119, 122, 128, 195, 197t, 321. See also *β-Blockers, clinical trials of; Bucindolol*.
- β-Adrenergic receptor density, 45, 48
- β-Blockers. See also *BEST; CAPRICORN; CIBIS; COMET; COPERNICUS; MERIT-HF; RESOLVD* entries; specific drugs.
 in ACC/AHA heart failure management guidelines, 65
 ACE inhibitors with, 121, 136, 137-138, 191, 198-199, 200t, 215-216
 adverse effects of, 136, 190-191, 194t-195t, 200t-201t
 for angina, 164
 for atrial fibrillation, 269, 270, 271t
 atrial-ventricular node conduction and, 269
 blood flow and, 54
 characteristics of, 192-193, 195, 196t
 clinical trials of, 47, 96t-97t, 101t, 105t, 108t-109t, 112t, 114t-116t, 119, 120-123, 126-129, 183, 191-192, 192-193, 195, 201, 216, 321
- β-Blockers (*continued*)
 in combination therapy, 138, 198, 218t
 contraindications to, 191, 200t
 daily protocol for, 191, 198-199, 200t, 220, 220t
 discontinuation of, 135t
 diuretics with, 200t-201t
 dobutamine interaction with, 247, 249t
 dosage of, 166-168, 194t, 200t, 217, 230t, 247
 decreased, 199, 201t, 221, 223
 inadequate, 156t, 230t
 effectiveness of, 137, 189, 192-193, 196, 197t, 198
 end point mortality with, 189, 191, 192-193, 197t
 endocrinopathy and, 18t, 19
 FDA approval of, 191
 generations of, features of, 196t
 guidelines for use of, 315, 318t
 heart rate and, 221
 indications for, 45, 48, 135t-136t, 161, 162-165, 166, 198, 200t, 217, 218t, 268-269, 270
 after infarct exclusion surgery, 305t
 milrinone with, 247
 NYHA classification and, 191, 196, 198
 pacing and, 199
 preventive, 159
 after Q wave myocardial infarction, 191
 selective/nonselective, 191, 196t
 sotalol as, 268
 for volume overload, 161, 162-164, 166
- Betapace. See *Sotalol*.
- Betaxolol, 196t
- Biochemistry screen, 80t, 81
- Bisoprolol (Zebeta)
 adverse effects of, 194t
 clinical trials of, 97t, 104t, 109t, 119, 121-122, 128, 198. See also *CIBIS* entries.
 dosage of, 194t
 effectiveness of, 191, 192
 features of, 193, 196t
 mortality end points with, 197t
 preventive, 159
- Blood flow. See *Cardiac output*.
- Blood pressure. See also *Hypertension; Hypotension*.
 self-monitoring of, 141
 volume overload and, 166
- Blood urea nitrogen (BUN), 79, 80t
- BMS-186716, metalloprotease inhibition by, 108t, 323t. See also *IMPRESS*.
- BNP (Breathing Not Properly) trial, 102t, 227-228, 228, 321
- Body temperature, 72
- Body volume, in acute vs chronic heart failure, 22t, 232t
- Bone marrow suppression, 170t
- Bosentan, 106t, 322
- Bradycardia, 258t
 β-blockers in, 199, 201t
 in sudden cardiac death, 151, 151t, 152
- Brain natriuretic peptide
 bioavailability of, 20
 blood flow and, 52, 58, 61
 in clinical trial, 102t, 321
 diagnostic importance of, 75, 79, 80t, 81, 227-229, 228
 distinguishing features of, 76t-77t, 78
 level in acute decompensated vs stable chronic heart failure, 23t, 233t
 metabolism of, 78
 parenteral, hemodynamic effects of, 242t
 rapid assay for, 74
 source of, 61t
 therapy guided by, 213, 214t, 217, 219-220, 253
- Bronchitis
 infectious, 154
 untreated, 156t
- Bronchodilators, 155t, 218t
- Bronchospastic disease, sotalol in, 268
- Bruce exercise test, 86, 88
- B-type natriuretic peptide. See *Brain natriuretic peptide*.

- Bucindolol
 action mechanism of, 193, 195, 196t
 clinical trials of, 97t, 101t, 122t, 128, 195, 197t. See also *BEST*.
- Bumetanide (Bumex)
 adverse effects of, 170t
 bioavailability of, 176
 dosage of, 170t, 177t
 Bumex. See *Bumetanide*.
- CABG Patch, 97t, 102t, 284t, 321
- Cachexia, 72
- Calcification, vascular/cardiac, 83t
- Calcium
 in actin-myosin cross-bridge formation, 44
 troponin C binding to, 41
- Calcium channel blockers
 adverse effects of, 129, 134, 135t, 157t, 203, 207t
 clinical trials of, 97t, 108t, 115t, 126-127, 168, 215, 216
 contraindications to, 203
 dosage of, 207t
 indications for, 159, 167, 271t
 mortality and, 129
- CAMIAT, 96t, 102t, 123, 321. See also *Amiodarone, clinical trials of*.
- Canadian Cardiovascular Society, guidelines on heart failure treatment, 317t
- Candesartan (Atacand)
 adverse effects of, 202t, 206t
 clinical trials of, xiv, 96t, 103t, 114t-115t, 125, 199. See also *CHARM; STRETCH study*.
 dosage of, 126, 202t, 206t
 effectiveness of, 168, 199, 201, 203
 indications for, 162-163, 166, 189
 mortality and, 137, 201
- Capillary wedge pressure
 in decompensation, 240t
 in parenteral drug therapy, 242t-243t
- Capoten. See *Captopril*.
- CAPP, 97t, 102t, 321. See also *Captopril, clinical trials of*.
- CAPRICORN, 97t, 102t, 123, 125, 128, 191, 195, 197t, 321. See also *β-Blockers, clinical trials of; Carvedilol, clinical trials of*.
- Captopril (Capoten)
 adverse effects of, 188t
 clinical trials of, 96t-97t, 102t-103t, 105t, 107t, 109t, 114t, 116t, 125, 321. See also *CAPP; CATS; Hy-C*.
 dosage of, 187, 188t
 effectiveness of, 99
 in elderly patients, 105t
 mortality end points and, 186
 preventive, 102t
- Carafate (sucralfate), 212
- Carbamazepine (Tegretol), 212
- Carbohydrate metabolism, 177t
- Cardiac anatomy, diagnostic determination of, 67
- Cardiac decompensation, 17, 18t. See also *Decompensated heart failure*.
- Cardiac index
 in decompensated heart failure, 225, 226t, 227
 prognosis and, 143, 145
- Cardiac injury, heart failure from, pathophysiology of, 38-39, 40
- Cardiac interstitium. See *Interstitialium*.
- Cardiac metastasis, 156t
- Cardiac output
 autoregulation of, 53, 54
 in decompensation, 240t
 hemodynamic patterns in, 21, 25t
 in idiopathic tachycardia, 31t
 low, 41, 53
 neurohumoral regulation of, 52, 53
 in parenteral drug therapy, 242t-243t
 preload/afterload in, 53, 55
 therapeutically increased, 19
- Cardiac pump. See *Pump entries*.
- Cardiac resynchronization. See *Pacing*.
- Cardiac surgery. See *Surgical treatments*.
- Cardiac transplantation
 in ACC/AHA heart failure management guidelines, 65
 contraindications to, 309, 310t
 indications for, 17, 252t, 310t-311t
 new surgical approaches to, 306
 NYHA classification and, 308
 problems with, 306
 survival time after, 293
- Cardiogenic shock. See also *SHOCK study*.
 hemodynamic patterns in, 240t
 intra-aortic balloon counterpulsation for, 237
 in low cardiac output, 25t, 41
- Cardiomegaly, 22t, 232t
- Cardiomyopathy. See specific classification, eg, *Hypertrophic cardiomyopathy*.
- Cardiomyoplasty, dynamic, 252t
- Cardiopulmonary resuscitation, patient/family education on, 142t, 143
- Cardiotoxin use, ACC/AHA heart failure management guidelines in, 65
- Cardiovascular examination, in heart failure diagnosis, 70t, 72, 73t, 74
- Cardioversion
 for atrial fibrillation, 165, 167
 chemical, 266, 271
 electrical, 271
 stroke risk in, 266
 with transesophageal echocardiographic guidance, 266-267, 270
 warfarin before, 266
- Cardioversion defibrillators, implanted. See also *SCD-HeFT*.
 indications for, 153, 258t
 in pacing, 259
 trials of, xiv, 97t, 101t, 108t, 124-125, 128. See also *CIDS; MADIT; MIRACLE* entries.
- Cardura (doxazosin), 100t, 206t
- CARE-HF, 264t, 321
- Carteolol, 196t
- Carvedilol (Coreg). See also *CAPRICORN; COMET; COPERNICUS; MOCHA; PRECISE/MOCHA*.
 action mechanism of, 193, 195, 196t
 adverse effects of, 194t, 200t-201t
 clinical trials of, 47, 97t, 102t-104t, 109t-110t, 112t, 119, 121, 122-123, 191, 192-193, 195-196, 198, 321
 in combination therapy, 128
 dosage of, 122, 194t-195t, 198, 200t
 effectiveness of, xiv, 122-123, 128, 191, 192, 196, 197t
 FDA approval of, 191
 indications for, 159, 191, 195t, 200t-201t
 mortality with, 47
 preventive, 159
- CARVEDILOL trial, 322
- CASH, 97t, 103t, 282t, 321
- CASS, 98t, 103t, 322. See also *Surgical treatments*.
- CAST, 103t, 123, 267, 322. See also *Antiarrhythmics, clinical trials of*.
- Catapres (clonidine), 205, 207t
- Catecholamines, 33t, 36, 148t, 152
- Catheter ablation, for atrial fibrillation, 272-273, 276t-278t
- Catheterization
 clinical trials of, 90t, 98t, 323-324t
 complications of, 238t
 diagnostic, 68, 82
 of pulmonary artery, 98t, 106t, 323
 of right heart
 to determine filling pressure, 166
 indications for, 236-237
- CATS, 95, 96t, 103t, 322. See also *Captopril, clinical trials of; Thrombolysis, clinical trials of*.
- Causes of heart failure, 29-40
- Celiprolol, 196t
- Cellulitis, untreated, 156t
- Central nervous system
 cardiac output and, 52, 53, 55
 contractility and, 53
- Cerebrovascular accident
 in cardioversion, 266
 in sudden cardiac death, 151
- Chagas disease, 31t, 35
- CHARM, 96t, 103t, 120, 125-126, 168, 201, 322. See also *Candesartan, clinical trials of*.

- Chemotherapy, decompensated heart failure and, 230t
- Chest wall deformity, 90t
- Chest X-ray
 - information from, 82, 83t
 - in systolic vs diastolic dysfunction, 91t
- CHF-STAT, 96t, 104t, 124, 322. See also *Antiarrhythmics, clinical trials of*.
- Chibroxin (norfloxacin), 212
- Chloral hydrate, 212
- Chlordiazepoxide (Limbitrol), 212
- Chlorothiazide (Diuril), 170t, 174
- Chlorthalidone (Hygroton), 100t, 171t
- Cholestyramine (LoCholest, Questran), 212
- Chronic heart failure
 - decompensated. See *Decompensated heart failure*.
 - stable, 22t-23t
- Chronic obstructive pulmonary disease
 - decompensated heart failure and, 229, 230t
 - management of, 155t, 218t, 219
 - untreated, 156t
- Chymase, 57, 59
- CIBIS-I, 97t, 104t, 121, 322
- CIBIS-II, 97t, 104t, 119, 121, 192, 197t, 198
- CIDS, 104t, 282t, 322. See also *Cardioversion defibrillators, implanted*.
- Cimetidine (Tagamet), 212
- Classification of heart failure etiologies, 30, 31t-33t, 33-37, 40
- Clinical trials. See also specific drugs and specific trials.
 - advantages and disadvantages of, 94t
 - number of, 93
- Clonidine (Catapres), 205, 207t
- Clopidogrel, 218t
- Collagen, interstitial, cardiac stiffness and, 44
- COMET, 45, 47, 97t, 104t, 121-122, 191-192, 195t, 197t, 198, 322. See also *β-Blockers, clinical trials of; Carvedilol, clinical trials of; Metoprolol CRXL, clinical trials of*.
- Comorbid conditions, 154, 155t, 156t-157t. See also specific condition, eg, *Diabetes mellitus*.
- COMPANION, 97t, 264t, 293t, 322
- Computed tomography (CT)
 - advantages of, 85t, 86
 - indications for, 84
 - limitations of, 85t, 86
- Congestive heart failure. See also *Decompensated heart failure; Filling pressure; Volume overload*.
 - β-blockers and, 199, 201t
 - death from, 26
 - diuretics for, 168-169
 - drug selection in, 96t-97t, 168, 177
 - exercise in, 21, 24
 - lifetime risk for, 24, 26, 26t
 - in muscular dystrophy, 29, 33t
 - pacemakers for, 246t. See also *COMPANION; MIRACLE; SCD-HeFT*.
- Connective tissue disorders, 32t
- CONSENSUS, 95, 96t, 99, 104t, 119, 150t, 184, 322. See also *Enalapril, clinical trials of*.
- Contact CD, 263t, 322
- Continuous positive airway pressure device, 218t
- Contractility
 - cardiac inotropic properties in, 53
 - heart rate and, 55
 - regulators of, 41, 43t, 44
- Contrast-induced nephropathy, 148
- COPD. See *Chronic obstructive pulmonary disease*.
- COPERNICUS, 97t, 104t, 119, 128, 193, 196, 197t. See also *β-Blockers, clinical trials of; Carvedilol, clinical trials of*.
- Cordarone. See *Amiodarone*.
- Coreg. See *Carvedilol*.
- Coronary angiography, 144
- Coronary arteriography, 148
- Coronary artery bypass graft patch, 102t, 321
- Coronary artery disease. See also *Ischemic heart disease*.
 - heart failure caused by, 143-145, 146-147, 148-149
 - treatment of, in heart failure, 146-147, 218t
- Coronary revascularization, 252t
- Corvert (ibutilide), 271t
- Cough, ACE inhibitors and, 188t, 189, 190t
- Counseling of patient and family, 140-143, 142t
 - dietary, 140
 - in hypotension, 219-221
- Cozaar. See *Losartan*.
- C-reactive protein, high sensitivity, 80t
- Creatinine, in serum, 79, 80t
- Cross-bridge formation
 - calcium concentration and, 41, 44
 - energy for, 44
- C-type natriuretic peptide, 61t
- Cyclooxygenase (COX)-2 antagonists, 154
- Cyclosporine (Neoral, Sandimmune), 110t, 212
- Cytokine antagonists, 113t. See also *RENAISSANCE*.
- Cytokines, 18t, 19, 62, 63, 79
- Cytomegalovirus, 31t, 35
- Darvon (propoxyphene), 197
- DAVID, 322
- Death from heart failure
 - ACE inhibitors and, 184-187
 - age and gender and, 26
 - age, gender, and race and, 21, 26, 26t, 27, 143, 144
 - antiarrhythmics and, 124
 - β-blockers and, 189, 191, 192-193
 - brain natriuretic peptide level and, 75, 79
 - clinical studies of, 127
 - drugs reducing, 135t
 - incidence of, 26t
 - sudden. See also *SCD-HeFT; Ventricular arrhythmia*.
 - causes of, 152
 - clinical studies of, 101t-102t, 114t
 - drug-induced, 135t0, 152
 - incidence of, 149, 150t, 273, 280
 - mechanism of, 149, 151, 151t, 153
 - oral inotropic agents and, 129
 - prevention of, 280, 282t-285t. See also *Pacer-defibrillator, biventricular*.
- Decompensated heart failure, 20, 22t-23t, 37t. See also *Filling pressure; Volume overload*.
 - clinical features of, 17, 18t, 225, 226t
 - hemodynamics in, 226t, 227, 238, 240t, 242t-243t, 248t-249t
 - home care for
 - basics of, 231, 235t
 - indications for, 234t
 - monitoring in, 235t, 251
 - hospitalization for
 - indications for, 231, 253, 234t, 251
 - therapeutic goals and interventions in, 231, 234, 235t, 236
 - hypertension in, 229, 230t
 - hypotension in, 165
 - invasive hemodynamic monitoring in, 236-238, 238t-239t
 - laboratory findings in, 226t, 227
 - in low cardiac output, 25t
 - new agents for, 239, 241
 - parenteral drug therapy in
 - advantages and disadvantages of, 238
 - agent adverse effects in, 244t
 - hemodynamic effects of, 242t-243t
 - predisposing factors and patterns for, 229, 230t
 - therapy for
 - algorithm for, 253
 - goals in, 241, 246t, 250-251
 - protocols in, 241, 247, 248t-249t
 - vasodilators in, 234, 235t, 236
 - ventricular hypertrophy and, 17, 18t
 - vs acute and stable chronic heart failure, 232t-233t
- Deconditioning, cardiovascular, 156t, 230t
- Defibrillators. See *Cardioversion defibrillators*.
- Definitions of heart failure, treatment and, 17, 18t, 19
- Demdex (torsemide), 170, 176, 177t
- Dendroaspic natriuretic peptide, 61t
- Dermatomyositis, 32t, 35
- Desyrel (trazodone), 212

- Diabetes mellitus, 32t, 35
 ACC/AHA heart failure management guidelines in, 65
 angina in, 167
 clinical trials of, 107t, 109t
 as comorbid condition, 154, 155t-156t
 decompensated heart failure and, 230t
 drug combinations for, 213, 215, 218t
 heart failure treatment in, 320t
 hibernating myocardium in, 299t
 management of, 155t, 218t, 219
 self-monitoring in, 141
- Diagnosis of heart failure
 cardiac catheterization in, 67, 68
 exercise testing in, 68
 functional capacity assessment in, 68, 86, 88-89
 imaging tests in, 67, 68, 82, 83t, 84, 85t, 86, 91t
 integrating components of, 67, 69t
 laboratory tests in, 67, 68, 79, 80t, 81
 natriuretic peptides in, 74-75, 76t-77t, 78, 79
 patient history in, 68, 69, 70t-71t, 71-72, 91t
 ACC/AHA classification in, 69
 physical examination in, 68, 72, 73t, 74
 pitfalls in, 154, 156t-157t, 157-158
- Dialysis, chronic, 252t
- DIAMOND-CHF, 96t, 105t, 124, 322
- DIAMOND-MI, 96t, 105t, 124, 322
- Diastole
 dysfunctional, 20
 diagnosis of, 91t
 in heart failure, 41
 myocardial interstitium in, 17, 19, 62, 64t
 in energy store utilization, 44
 left ventricular, neurohormonal regulation of, 52
 myofilaments in, 41
- Diastolic wall stress, in volume overload, 50
- Dicloxacillin, 212
- Diet, salt-restricted, 139-140, 142, 156t
 in decompensation, 231, 235t
 diuretics and, 168-169
- Diflucan (fluconazole), 212
- DIG, 97t, 99, 105t, 119, 120, 168, 322
- Digoxin (Lanoxin)
 adverse effects of, 156t, 203, 204t-205t
 for atrial fibrillation, 269, 270, 273
 atrial-ventricular node conduction and, 269
 benefits of, 99, 120
 bradycardia and, 199, 201t
 clinical trials of, 95, 97t-98t, 99, 104t-108t, 111t-114t, 117t, 120, 168, 216, 324.
 See also *PROVED*; *RADIANCE*.
 in combination therapy, 95, 127-128, 137-138, 163, 198, 213, 215
 for congestive heart failure, 97t
 daily protocol for, 220t
 discontinuation of, 120, 156t
 diuretics with, 163
 dosage of, 204t-205t, 218t
 heart failure hospitalizations and, 203
 indications for, 18t, 128-129, 136t, 161, 163, 180, 203, 218t
 pharmacokinetics of, 269
 preventive, 159
 serum level of, 80t, 203, 205t
 for volume overload with borderline blood pressure, 166
- Dilantin (phenytoin), 80t, 212
- Dilated cardiomyopathy, 31t
 growth hormones for, 107t
- Diltiazem
 for atrial fibrillation, 269, 270, 271t
 bradycardia and, 199, 201t
 clinical trials of, 96t
- DIMT, 97t, 105t, 322. See also *Ibopamine*.
- Diovan. See *Valsartan*.
- Disopyramide (Norpace and others), 271t
- Disulfiram (Antabuse), 212
- Diuretics. See also specific drugs.
 in ACC/AHA heart failure management guidelines, 65
 ACE inhibitors with, 138, 171t, 182t, 190t, 215, 236
 adverse effects of, 79, 138-139, 154, 156t-157t, 157, 175t-176t
 algorithm for, 172-174
 arrhythmia and, 152
 β -blockers with, 200t-201t
 clinical trials of, 95, 100t, 102t, 104t-108t, 111t-113t, 115t, 117t, 120-121t, 127-128, 183, 216
 in combination therapy, 138, 198, 213, 217
 for congestive states, 168, 215, 231, 235t
 daily protocol for, 169, 220t, 231, 235t
 for decompensation, 236, 248t
 digoxin with, 163
 discontinuation of, 175t
 dosage of, 138, 157, 163-164, 177t, 181, 189, 190t, 199, 221, 223, 230t, 235t
 for dyspnea, 164, 166-167
 in elderly patients, 169, 175t
 electrolytes and, 61
 excessive, 156t, 175, 219
 herbal, 17
 in hospitalized patient, 255t
 indications for, 18t, 136t, 137, 140, 175t, 215, 217, 218t, 221
 loop, 100, 170t, 175t-177t, 183, 220t, 231, 241
 nesiritide and, 241, 245t, 251
 NYHA classification and, 169, 172
 pharmacokinetics of, 176-177
 potassium-sparing, 159, 169, 171t, 176t, 190t
 preventive, 159
 for pulmonary edema, 250t
 rationale for, 17, 18t
 renal concentrations and, 60
 thiazide, 100t, 169, 171t, 177, 218t
 types of, 169, 170t-171t
 for volume depletion, 169, 172-173, 219, 221, 234
 for volume overload, 163-164, 166
 weight monitoring and, 169
- Diuril (chlorothiazide), 170t, 174
- Dobutamine
 adverse effects of, 231, 234, 249t
 β -blocker interaction with, 247
 dosage of, 246t, 249t
 hemodynamic effects of, 242t, 247, 249t
 indications for, 231, 247, 251
 in ischemic heart disease evaluation, 145, 148t
 LIDO trial of, 97t, 108t, 323
 parenteral, 242t
 in stress echocardiography, 82, 145, 297
- Dofetilide (Tikosyn), 96t, 105t, 124, 271t, 322
- Dopamine
 adverse effects of, 244t
 hemodynamic effects of, 242t-243t
 indications for, 231, 247, 249t
- Doppler studies, 67, 74t, 75, 77t
- Dor procedure, 231t, 258-259
- Doxazosin (Cardura), 100t, 206t
- Dropsical condition, 15, 16t, 17, 18t
- Duchenne muscular dystrophy, 33t, 36
 cardiomyopathy in, 29, 33t
 remodeling in, 45
- Dyslipidemia, 156t
- Dyspepsia, 215
- Dysphoric syndromes, 215
- Dyspnea, 71
 angina and, 167
 β -blockers and, 199, 201t
 diuretics for, 164, 166-167
 drug selection in, 162-164, 167
 noncardiac causes of, 90t
 sudden inexplicable, 144

- Echocardiography
 dobutamine stress, 82, 145, 297
 in systolic vs diastolic dysfunction, 91t
 transesophageal, 266-267, 270
 two-dimensional/M-mode, 67, 83t, 84, 85t
- Edecrin (ethacrynic acid), 170t, 175, 176t-177t
- Edema. See also *Pulmonary edema*.
 ACC/AHA heart failure management guidelines in, 65
 in heart failure diagnosis, 71t
 lower extremity, 71
 peripheral, 225
 treatment of, 17, 18t
- Effusion
 pericardial, tamponade from, 37t
 pleural, 225
- Efudex (fluorouracil), 212
- Ejection fraction
 in atrial fibrillation management, 258t, 270
 defibrillators and, 124-125
 left ventricular
 on COMET, 45, 47
 heart failure pathophysiology in, 87
 low
 anticoagulants for, 135t, 136-137
 drug selection in, 168
 neurohormones and, 53, 56, 57
 in pacemaker decisions. See *COMPANION; MIRACLE* entries; *SCD-HeFT*.
 prognosis and, 143, 145
 valve repair/replacement and, 299-300
- Elderly patients
 captopril in, 105t
 diuretics in, 169, 175, 175t
 losartan in, 105t. See also *ELITE* entries.
- Electrocardiogram, signal averaged, 288
- Electrocardiography
 information from, 83t, 84
 in systolic vs diastolic dysfunction, 91t
- Electrolytes
 abnormalities of, 32t, 35, 157t
 in decompensation, 230t, 234t
 in diuretic therapy, 169, 170t, 175, 175t, 177t
 in serum, 79, 80t
- Electrophysiologic studies
 indications for, 286t, 287
 in left ventricular dysfunction, 258t
 in ventricular tachycardia, 288-289
- Electrophysiologic treatment, 149, 150t-151t, 151, 152, 153, 153t. See also *Arrhythmia*.
- ELITE, 96t, 105t, 125, 322. See also *Losartan, clinical trials of*.
- ELITE-II, 96t, 105t, 125, 322
- ELVD, 98t, 106t, 322
- Emergency department diagnosis, brain natriuretic peptide in, 75
- EMIAT, 96t, 106t, 123, 322. See also *Amiodarone, clinical trials of*.
- ENABLE trial, 106t, 322
- Enalapril (Vasotec)
 adverse effects of, 188t
 clinical trials of, 95, 96t, 99, 104t, 111t, 114t-115t, 117t, 119, 150t, 185, 322, 324.
 See also *CONSENSUS*.
 dosage of, 187, 188t
 effectiveness of, 99
- Encainide, 103t, 123, 267
- Endocarditis, cardiomyopathy and, 31t, 35
 valvular regurgitation in, 37t
- Endocrine disorders
 cardiomyopathy and, 32t
 heart failure as, 18t, 19
- Endothelin, vasoconstriction and, 54
- Endothelin antagonist, 106t, 322
- Endothelin receptor antagonist, parenteral, hemodynamic effects of, 242t
- Endothelium-derived relaxing factor, 53, 54
- Endoventricular patch reconstruction, 252t
- Enoximone, 97t, 106t, 322
- Enterovirus, 31t, 35
- Environmental temperature extremes, 229, 230t
- Ephedra, 135t
- EPHESUS, 106t, 127, 183, 323
- Epidemiology of heart failure, 21, 24, 26, 26t
- Epinephrine
 adverse effects of, 244t
 clinical trials of, 57, 105t
 dopamine and, 243t
 ejection fraction and, 56
 mortality/morbidity and, 213
 parenteral, hemodynamic effects of, 243t
 remodeling and, 47
 vasoconstriction and, 54
 vasodilation and, 53
- Eplerenone (Inspra)
 ACE inhibitors with, 127
 adverse effects of, 182, 183
 β -blockers with, 127
 clinical trials of, 98t, 106t, 127, 137, 183, 323
 dosage of, 181-182
 indications for, 177
 after myocardial infarction, 165, 180
- Erythromycin, 212
- ESCAPE, 98t, 106t, 323. See also *Catheterization*.
- Etanercept, 98t
- Ethacrynic acid (Edecrin), adverse effects of, 170t, 175, 176t-177t
- Ethmozine (moricizine), 123, 271t
- Etretinate (Tegison), 212
- European Society of Cardiology, guidelines on heart failure treatment, 316t-317t
- Evidence-based drug therapy, 137-139
- Excitation, regulators of, 41, 43t, 44
- Exercise
 aerobic, 140
 clinical trials of, 98t, 106t, 113t, 322. See also *ELVD*.
 in congestive heart failure, 21
 decreased tolerance of, 71
 ACC/AHA heart failure management guidelines in, 65
 discouraged by physicians, 139-140
 guidelines for, 316t-317t
 lack of response to, 266
- Exercise radionuclide scintigraphic studies, 82
- Exercise testing, 68, 86
 evaluation of, 86-87
 in hibernating myocardium, 148t
 intolerance of, noncardiac causes of, 71, 90t
 metabolic, 87, 88
 NYHA classification and, 88-89
 protocols for, 86-87, 88
- Extra myocyte matrix. See *Interstitium*.
- Fabry-Anderson disease, 32t
- FACET, 107t, 323. See also *Flosequinan, clinical trials of*.
- Familial disorders/diseases
 cardiac contractile protein production abnormalities from, 30, 31t, 33t
 cardiomyopathy as, 29, 42
 Mediterranean fever as, 32t
 storage disease/infiltration as, 32t, 35
- Family counseling, 140-142, 142t, 318t
- Fatigue, nonspecific, 71
- Felodipine (Plendil)
 adverse effects of, 134, 203, 207t
 clinical trials of, 97t, 117t, 127, 129
 dosage of, 207t
 for hypertension, 164, 167
 indications for, 164
- Fetal myocyte phenotype, reversion to, 62, 64t
- Fever, heart failure as, 18t
- Fibrillation, atrial. See *Atrial fibrillation*.
- Fibroelastosis, 31t, 34
- Fibrosis, myocardial, inflammation and, 19

Filling pressure. See also *Decompensated heart failure; Volume depletion; Volume overload.*
 diagnostic catheterization in, 166
 diuretic selection and, 172
 rate control and, 261
 signs and symptoms of, 172
 therapeutically decreased, 19
 FIRST, 98t, 107t, 119, 323. See also *Angiotensin-converting enzyme (ACE) inhibitors, clinical trials of.*
 Fistula, peripheral arteriovenous, 37t
 Flagyl (metronidazole), 212
 Flash pulmonary edema, 20, 144, 299t
 Flecainide (Tambacor), 103t, 123, 267, 271t
 Fliolan, 107, 119. See also *FACET.*
 Flosequin, 98t, 107t, 112t-113t, 127. See also *FACET; PROFILE; REFLECT.*
 Floxin (ofloxacin), 212
 Flu vaccination, 154
 in COPD, 155t
 warfarin interaction with, 212
 Fluconazole (Diflucan), 212
 Fluid restriction, 139, 140, 142, 156t
 in ACC/AHA heart failure management guidelines, 65
 in decompensation, 231, 235t
 diuretics and, 168-169
 Fluid retention, 41, 320t. See also *Edema.*
 NSAIDs and, 136
 oral hypoglycemic agents and, 134
 Fluorouracil (Efdex), 212
 Fosinopril (Monopril), 188t
 Foxglove tea, 17, 18t
 Framingham heart study
 death rate from heart failure in, 143, 144
 incidence rates in, 24, 26, 26t, 28
 Friedreich's ataxia, 33t
 Fulvicin (griseofulvin), 212
 Fungal endocarditis, 31t, 35
 Furosemide (Lasix)
 adverse effects of, 170t, 175, 177t
 bioavailability of, 176
 dosage of, 170t, 173-174, 177, 177t
 metolazone before, 231, 235t
 nesiritide and, 244, 248t
 for pulmonary edema, 250t
 for volume overload, 173-174
 FUSION, 256
 Gadolinium MRI, 82, 84, 148t, 297, 304, 305t
 Galactorrhea, 177t
 Gastroenterologic system, in heart failure diagnosis, 70t
 Gender and heart failure, 26, 28
 death rate and, 143, 144
 GESICA, 96t, 107t, 119, 123, 323
 Giant cell myocarditis, 31t, 34
 GISSI-III trial, 99, 100t
 Glycogen storage disease, 32t, 35
 Gout, 218t
 Granulomas, 32t, 35
 Grisactin (griseofulvin), 212
 Griseofulvin (Fulvicin, Grisactin), 212
 Growth hormone, 98t, 107t
 Growth hormone receptors, myocardial hypertrophy and, 45
 Guanabenz (Wytensin), 207t
 Guanfacine (Tenex), 207t
 Guidelines for heart failure management
 common themes in, 313-315, 318t
 limitations of, 313, 314t, 315
 presently available, 65, 132, 316t-317t
 in special situations, 319t-320t
 third-party payers and, 314
 Gynecomastia, 177t, 181

Hand-Schuler-Christian disease, 32t
 Heart, transplantation of. See *Cardiac transplantation.*

Heart block, 258t
 complete, in sudden cardiac death, 151, 151t, 152
 Heart disease, structural, ACC/AHA heart failure management guidelines in, 65
 Heart murmur, 74
 Heart rate
 contractility and, 53, 55
 in parenteral drug therapy, 242t-243t
 resting, prognosis and, 143
 Hemochromatosis, 32t, 35
 Hemodynamic monitoring, invasive, 236-238, 238t
 Hemodynamics
 in decompensation, 226t, 227, 237-238, 240t-243t
 in low cardiac output, 21, 25t
 in parenteral drug therapy, 242t-243t
 Hemoglobin A_{1c}, 80t, 81
 Henle's loop, neurohormonal effects on, 57, 58t
 Heparin
 for atrial fibrillation, 270
 in hospitalized patients, 237t
 nesiritide and, 244, 248t
 for venous thrombosis prevention, 236
 Hepatojugular pulsatility/tenderness, 225, 226t
 Herbal diuretics, 17
 Hibernating myocardium. See also *Ischemic heart disease.*
 conditions favorable for, 298, 298
 diagnosis of, 298-299, 299t
 identifying viability in, 148t, 149
 response to increased coronary flow, 298, 298
 viability assessment in, 297-298
 HIPPOCRATES, 98t
 History taking, 68, 69, 70t-71t, 71-72
 in systolic vs diastolic dysfunction, 91t
 Home care for heart failure
 basics of, 231, 235t
 monitoring of, 235t, 251
 HOPE, 95, 97y, 107t, 109, 323
 Hospice care, 251, 252t
 Hospitalization for heart failure
 cost of, 26t, 158
 digoxin and, 203
 duration of, 251
 frequency of, xiii, 24, 26t
 indications for, 231, 234t
 monitoring in, 236
 readmission rate in, 26t, 158
 therapeutic goals and interventions in, 231, 235t, 236, 237t
 Human B-type natriuretic peptide, 61t
 Human immunodeficiency virus, 31t, 35
 Hurler's syndrome, 32t, 35
 Hy-C, 98t, 107t, 323. See also *Captopril, clinical trials of; Hydralazine, clinical trials of.*
 Hydralazine (Apresoline). See also *Hy-C.*
 ACE inhibitors with, 205
 adverse effects of, 204t, 205, 207t
 clinical trials of, 95, 98t, 107t, 117t, 185t, 323
 digoxin with, 138
 diuretics with, 138
 dosage of, 203, 204t, 205, 207t
 for dyspnea, 164, 167
 heart failure mortality and, 94, 135t
 indications for, 135t, 137, 159, 166, 190t
 preventive, 159
 Hydrochlorothiazide (HydroDIURIL), 171t
 HydroDIURIL (hydrochlorothiazide), 171t
 Hygroton (chlorthalidone), 100t, 171t
 Hyperglycemia
 decompensated heart failure and, 230t
 diuretics and, 175, 177t
 Hyperkalemia
 ACE inhibitors and, 79, 188t-189t, 190
 in decompensated heart failure, 226t
 diuretic-induced, 176, 177t
 drug selection and, 79
 spironolactone-induced, 183

Hyperosmolar states, 175, 177t

Hypertension
 ACC/AHA heart failure management guidelines in, 65
 cardiomyopathy and, 31t
 drug selection in, 164, 167, 218t
 heart failure and, 17, 34, 37t, 65
 decompensated, 229, 230t
 myocardial injury from, 46t
 prevention of, 100t

Hypertensive crisis, 23t, 233t

Hyperthyroidism, 35

Hypertrophic cardiomyopathy
 causes of, 45
 heritable disorders and, 30, 33t
 types of, 31t, 33-34

Hyperuricemia, 177t

Hypocalciuria, 177t

Hypoglycemic agents, oral, adverse effects of, 134, 135t

Hypokalemia, 32t, 35
 in decompensated heart failure, 227
 diuretics and, 79
 sodium intake and, 175

Hyponatremia
 causes of, 79
 in decompensated heart failure, 226t, 227
 diuretics and, 169, 175, 177t

Hypotension
 ACE inhibitors and, 179, 184, 188t-189t
 diuretics and, 170t
 drug-induced, 244t
 management of, 165, 167-168
 metoprolol and, 191
 orthostatic
 algorithm for, 220-221, 222-223
 drug scheduling in, 220, 220t
 management of, 138, 157, 157t
 patient counseling in, 219-221
 symptoms of, 220-221

Hypothyroidism, 32t

Hypoventilation, untreated, 156t

Hypovolemic shock
 hemodynamic patterns in, 240t
 in low cardiac output, 25t

Hytrin (terazosin), 206t

Ibopamine, 98t, 105t, 112t, 129. See also *DIMT; PRIME-II*.

Ibutilide (Corvert), 271t

Idiopathic dilated cardiomyopathy, 33-34

Idiopathic hypertrophic subaortic stenosis, 31t, 33-34

Idiopathic right ventricular outflow tract tachycardia, 31t

IMAC, 98t, 107t, 323

Imaging, diagnostic, 68, 82, 83t, 84, 85t, 86
 in hibernating myocardium, 148t, 149

Immune modulation therapy, 98t, 100t

Immunoglobulin, intravenous, 98t, 107t, 323

Immunosuppressives, 110t

IMPRESS, 98t, 108t, 323

Imuran (azathioprine)
 clinical trials of, 110t
 warfarin interaction with, 212

Incidence of heart failure, xiii, 21, 24, 26t
 in Framingham heart study, 26t, 28

Infarct exclusion, 301, 302-303, 304, 305t. See also *Myocardial infarction*.

Infection
 cardiac transplantation and, 310t
 cardiomyopathy and, 31t, 35
 decompensated heart failure and, 230t
 untreated, 156t

Inflammation. See also *Anti-inflammatory drugs; Aspirin; Nonsteroidal anti-inflammatory drugs*.
 cardiomyopathy and, 31t, 33
 myocardial fibrosis from, 19

Influenza vaccination, 154
 in COPD, 155t
 warfarin interaction with, 212

Inherited disorders. See *Familial disorders/diseases*.

Inodilator, 248t

Inotropes, 17, 97t-98t
 in ACC/AHA heart failure management guidelines, 65
 adverse effects of, 111t, 231, 234
 arrhythmia and, 152, 234
 clinical trials of, 97t-98t, 111t, 113t
 indications for, 231-232
 infused, s256, 252
 mechanical assistance and, 113t

Inspira. See *Eplerenone*.

Insulin resistance, 175, 177t

InSync III, 264t

International Society for Heart and Lung Transplantation, 317t

Interstitium
 in cardiac contraction, 43t, 44
 cardiac stiffening and, 62, 64t
 components of, 43t, 44
 in diastolic dysfunction, 19, 62, 64t

Irbesartan (Avapro), 206t

Irradiation, 33t, 36

Ischemic heart disease, 31t, 34. See also *Coronary artery disease; Hibernating myocardium*.
 acute, 20
 in acute vs chronic heart failure, 233t
 chronic, myocardial viability determination in, 145, 146-147, 148t
 as comorbid condition, 156t
 frequency of, 143

ISIS-IV trial, 99, 100t

Ismo (isosorbide mononitrate), 204t

Isodril. See *Isosorbide dinitrate*.

Isoniazid, 212

Isoproterenol
 adverse effects of, 244t
 parenteral, hemodynamic effects of, 243t

Isosorbide dinitrate (Isodril, Sorbitrate)
 adverse effects of, 190t, 204t
 clinical trials of, 95, 98t, 117t
 diuretics with, 138
 dosage of, 204t
 indications for, 166
 mortality and, 94
 preventive, 159

Isosorbide mononitrate (Ismo), 204t

Joint disease, degenerative, 154, 155t
 drug combinations for, 213, 215
 management of, 155t

Jugular vein infection, 225

Kidney disease, heart failure treatment in, 319t

Kidneys
 cardiac output and, 52
 in heart failure, 60
 neurohormonal activation and, 58t

Kinins, 53, 54

Kwashiorkor, 32t, 35

Laboratory tests, 68, 79, 80t, 81

Lanoxin. See *Digoxin*.

Lasix. See *Furosemide*.

Law of Laplace, 300, 301

Left ventricular. See also *Ventricle, left*.

Left ventricular dysfunction
 ACC/AHA classification of, 64, 65
 ACC/AHA heart failure management guidelines in, 65
 asymptomatic, 64

Left ventricular ejection fraction, on COMET, 45, 47

Lentiginosis, 33t

Leukemia, 32t

Leukocytosis, 79

Levosimendan
 LIDO trials of, 97t, 108t, 323
 parenteral, 243t

LIDO, 97t, 108t, 323

Limbitrol (chlordiazepoxide), 212

Lipid abnormalities, 175, 177t

Lipid level, 80t

Lipid-lowering drugs
 for angina, 164
 indications for, 218t, 219
 trials of, 100t, 321, 97t

Lisinopril (Prinivil, Zestril)
 adverse effects of, 188t
 clinical trials of, 96t, 100t-101t, 108t, 321. See also *ATLAS*.
 dosage of, 188t
 effectiveness of, 99

Liver function tests, 80t

LoCholest (cholestyramine), 212

Loop diuretics, 100, 162-164, 166, 170t, 175t-177t, 175-176, 220t, 231, 241, 247.
 See also *Diuretics*; specific drugs.
 potassium and magnesium repletion with, 169, 175t

Lopressor. See *Metoprolol*.

Losartan (Cozaar)
 adverse effects of, 202t, 206t
 clinical trials of, 96t, 105t. See also *ELITE* entries.
 dosage of, 202t, 206t

Lotensin (benazepril), 186, 188t

Lovastatin (Mevacor), 212

Lupus, 32t, 35

Lymphocytic myocarditis, 31t, 34
 myocyte protein production and, 30

MACH, 97t, 108t, 119, 127, 323

MADIT, 97t, 108t, 124, 200, 204t, 280, 284t, 323. See also *Cardioversion defibrillators, implanted*.

Magnesium deficiency, 32t, 35

Magnesium supplementation
 for atrial fibrillation, 165
 diuretics and, 169, 175t, 177t
 dosage of, 179t

Magnetic resonance imaging (MRI)
 advantages of, 85t, 86
 in identifying viability in hibernating myocardium, 148t
 indications for, 84
 limitation of, 85t

Malignancy
 cardiac transplantation and, 310t
 myocardial/pericardial metastases in, 230t

Malignant ventricular arrhythmia, 34, 123

Malingering, 90t

Mavik. See *Trandolapril*.

Maxzide (triamterene), 171t

Maze surgery, 272, 295

MDC, 97t, 108t, 121, 323. See also *Metoprolol CR/XL, clinical trials of*.

Mechanical assist devices. See also *Ventricular assist devices*.

Mediterranean fever, familial, 32t

Mental acuity, 225, 226t

Mental status, in heart failure diagnosis, 70t, 71, 73t

MERIT-HF, 97t, 109t, 119, 121, 193, 197t, 198, 323. See also *β-Blockers, clinical trials of; Metoprolol CR/XL, clinical trials of*.

Mesenteric congestion, 71

Metabolic acidosis
 in decompensated heart failure, 226t, 227
 diuretics and, 177t

Metabolic alkalosis, 81

Metabolic disorders, cardiomyopathy and, 32t, 35

Metabolic performance, NYHA classification and, 88-89

Metalloprotease inhibition, 108t. See also *IMPRESS*.

Metastasis, to heart, 156t, 230t

Metolazone (Zaroxolyn)
 adverse effects of, 171t
 clinical trials of, 47
 dosage of, 171t
 before furosemide, 231, 235t
 for volume overload, 173-174
 warfarin interaction with, 212

Metoprolol succinate CR/XL (Toprol). See also *MERIT-HF*.
 adverse effects of, 194t, 200t-201t
 bioavailability of, 122-123
 clinical trials of, 47, 97t, 104t, 109t, 119, 121-122, 128, 193, 323
 dosage of, 122, 194t-195t, 198, 200t
 effectiveness of, 128, 191, 193, 195t, 198
 FDA approval of, 191, 195t
 indications for, 197t, 198, 200t-201t
 mortality and, 191
 preventive, 159

Metoprolol tartrate (Lopressor). See also *COMET*.
 adverse effects of, 194t
 bioavailability of, 122-123
 clinical trials of, 47, 97t, 103t-104t, 108t-109t, 114t, 121-122, 191, 198, 322-323, 325
 dosage of, 122, 194t-195t
 effectiveness of, 195t, 198
 features of, 193, 196t
 indications for, 159, 198
 mortality and, 122, 197t

Metronidazole (Flagyl), 212

Mevacor (lovastatin), 212

MEXIS, 97t, 109t, 323. See also *Metoprolol CR/XL, clinical trials of*.

MHFT, 96t, 109t, 323

Mibefradil, 97t, 108t, 127

Micardis (telmisartan), 206t

Microalbuminuria. See also *HOPE; MICRO-HOPE*.

MICRO-HOPE, 97t, 109t, 323

Midamor (Amiloride), 171t

Milrinone
 adverse effects of, 244t, 249t
 β-blockers with, 247
 clinical trials of, 97t-98t, 111t-112t, 127, 129, 324. See also *PROMISE*.
 for decompensation, 235t, 242t, 248t, 251
 dosage of, 247, 248t
 hemodynamic effects of, 242t, 247, 248t, 253
 indications for, 231, 247, 248t, 251
 parenteral, hemodynamic effects of, 242t

Minipress (prazosin), 117t, 206t

Minoxidil, 207t

MIRACLE, 97t, 109t, 262t-263t, 293t, 323. See also *Cardioversion defibrillators, implanted*.

MIRACLE-ICD, 009t, 97t, 263t, 293t, 323

Mitochondria, in cross-bridge formation, 44

Mitochondrial cardiomyopathy, 31t, 34

Mitral arrhythmia, sustained, 37t

Mitral regurgitation, flash pulmonary edema and, 20

Mitral valve, acute catastrophe of, 230t

Mitral valve insufficiency
 hemodynamic patterns in, 240t
 in low cardiac output, 25t
 pathophysiology of, 37t

Mitral valve regurgitation
 in acute vs chronic heart failure, 23t
 in decompensated heart failure, 226t
 after myocardial infarction, 37t
 in volume overload, 42, 46t

Mitral valve repair/replacement
 effectiveness of, 304
 for refractory heart failure, 251, 252t, 299-300, 300t

M-mode echocardiography, 83t, 84, 85t

MOCHA, 97t, 110t, 112t, 323. See also *Carvedilol, clinical trials of*.

Moexipril (Univasc), 186, 188t

Molecular basis of heart failure, 41, 42, 43t, 43-44

Monopril (fosinopril), 188t

Mood changes, in decompensated heart failure, 225, 226t

Moricizine (Ethmozine), 123, 271t

Morquio-Ullrich disease, 32t
 MOXCON, 98t, 110t, 323
 Moxonidine, 98t, 110t, 323
 Muscarinic receptors, in autoregulation of blood flow, 54
 Muscular dystrophy, 29, 33t, 36, 46t
 remodeling and, 45
 MUSTIC, 97t, 110t, 262t, 324
 MUSTT, 96t, 110t, 284t, 324
 Myocardial infarction
 ACE inhibitors/ARBs after, 96t
 CAPRICORN trial after, 123, 321
 chemical cardioversion after, 266-267
 complications of, 37t
 eplerenone after, 177
 heart failure from
 decompensated, 229, 230t
 pathophysiology of, 38-39, 40
 implanted cardioverter after, 124-125
 myocyte protein production and, 30
 necrosis and apoptosis after, 45, 46t
 previous, ACC/AHA heart failure management guidelines in, 65
 surgery for. See *Surgical treatments*.
 survival of, 96t, 101t, 321. See also *SMILE*.
 Myocardial injury
 clinical manifestations of, 42
 prevention of, 19
 routes of, 46t
 Myocardial remodeling. See *Remodeling*.
 Myocarditis, 31t, 37t
 Myocarditis treatment trial, 324
 Myocardium, hibernating
 conditions favorable for, 298, 298-299
 diagnosis of, 298, 299t
 response to increased coronary flow, 298, 298
 Myocyte(s)
 in cardiac contraction, 43t, 44
 passive tension of, in remodeled heart, 19
 Myofilament functions, 41
 Myosin-actin interaction, 41, 43-44
 Myosplint shape-changing device, 296, 304, 306, 307-308
 Myotonic muscular dystrophy, 33t, 36
 Myxomatous chorda tendinae rupture, 37t

 Nadolol, 192-193, 196t
 Nafcillin (Unipen), 212
 Nalidixic acid (NegGram), 212
 National Institutes of Health, guidelines on heart failure treatment, 316t
 Natrecor. See *Nesiritide*.
 Natriuretic peptides. See also *Atrial natriuretic peptide*; *Brain natriuretic peptide*.
 cardiac filling pressure and, 57-58
 ejection fraction and, 56, 57
 levels of, 80t
 renal effects of, 160, 58t
 Naughton exercise test, 86, 88
 Nebivolol, 196t
 Necrosis
 causes of, 45, 46t
 myocytic, apoptosis vs, 47-48, 49t
 NegGram (nalidixic acid), 212
 Neoral (cyclosporine), 212
 Nephropathy, contrast-induced, 148
 Nesiritide (Natrecor)
 for acute heart failure, 235t
 for cardiogenic pulmonary edema, 250t
 clinical trials of, 245t, 256t
 for decompensation, xiii-xiv, 248t
 diuretics and, 241, 251
 dosage of, 241, 244, 245t, 248t, 250t
 effectiveness of, 234, 236
 furosemide and, 244, 248t
 hemodynamic effects of, 242t, 244, 246, 248t
 heparin and, 244, 248t

 Nesiritide (Natrecor) (*continued*)
 indications for, 244, 253
 neurohormonal activation and, 234, 236
 pharmacokinetics of, 239, 241, 244
 in VMAC trial, 98t
 Neurohormone(s)
 in blood flow regulation, 52, 53
 ejection fraction and, 56
 response to heart failure, 57-58, 60, 61
 Neurohormone blockers, 17, 19
 Neurologic/neuropsychiatric symptoms, in heart failure diagnosis, 67t, 71, 73t, 74
 Neuromuscular disorders, 33t
 New York Heart Association functional classification, 92t, 213, 225, 318t
 ACC/AHA classification vs, 131, 133
 β -blockers and, 191, 195, 197t
 in cardiac transplantation decision, 310t
 diuretics and, 169, 172
 in exercise testing and metabolic performance, 88-89
 heart failure timeline and, 24
 hospital/home care and, 254t
 in pacemaker decisions, 259, 262t-264t, 266, 280-281. See also *COMPANION*;
 MIRACLE entries; *SCD-HeFT*.
 in SOLVD, 95
 therapeutic approach and, 131, 172
 Niemann-Pick disease, 32t
 Nitrates
 for angina, 164, 167
 discontinuation of, 189
 dosage of, 190t
 indications for, 203, 216, 218t, 220
 Nitric oxide, 53, 54
 Nitroglycerin
 dosage of, 249t
 hemodynamic effects of, 242t, 244, 246, 249t
 indications for, 249t-250t
 in myocardial function assessment, 148t
 tachyphylaxis in, 249t
 in VMAC trial, 117t
 Nitroprusside
 adverse effects of, 244t
 for decompensation, 253
 dosage of, 246-247
 effectiveness of, 234, 236
 hemodynamic effects of, 242t, 246, 249t, 253
 monitoring of, 246, 250t, 253
 Nolvadex (tamoxifen), 212
 Noninvasive cardiac imaging, 82. See also *Imaging, diagnostic*.
 Nonischemic cardiomyopathy, 288
 Nonobstructive cardiomyopathy, hypertrophic, 31t, 34
 Nonpharmacologic therapies, 136t, 139-140, 315, 318t. See also specific therapy,
 eg, *Exercise*.
 Nonsteroidal anti-inflammatory drugs (NSAIDs). See also *Aspirin*.
 adverse effects of, 154, 157t, 217, 221, 230t
 contraindications to, 218t
 decompensation and, 250t
 discontinuation of, 135t, 189, 190t
 indications for, 218t
 renal effects of, 136, 190t, 214
 Noonan's syndrome, 33t
 Norepinephrine
 adverse effects of, 244t
 in clinical trials, 105t, 213
 ejection fraction and, 56, 57
 hemodynamic effects of, 243t
 remodeling and, 47t
 Norfloxacin (Chibroxin, Noroxin), 212
 Noroxin (norfloxacin), 212
 Norpace (disopyramide), 271t
 Norvasc. See *Amlodipine*.
 NSAIDs. See *Nonsteroidal anti-inflammatory drugs*.
 Nutritional disorders, 32t, 35

- Obesity
 decompensated heart failure and, 230t
 exercise intolerance in, 90t
 heart failure treatment and, 156t
- Obliterative cardiomyopathy, hypertrophic, 31t, 33-34
- Ofloxacin (Floxin), 212
- Olmesartan (Benicar), 206t
- Omapatrilat, 98t, 99, 111t, 324
- OPTIME-CHF, 97t, 111t, 231, 324
- Organ perfusion, therapeutically increased, 19
- Orthopnea, 69
- Orthostatic symptoms. See *Hypotension, orthostatic*.
- Ototoxicity, 173, 177t
- Outpatient heart failure management, 251-252, 254t-255t, 256
- OVERTURE, 96t, 99, 111t, 324
- Oxprenolol, 196t
- Oxygen, maximal consumption of, 86-87, 88, 143, 145
- Oxygen saturation, venous, in decompensated heart failure, 226t, 240t
- Pacer-defibrillator, biventricular
 algorithm for, 281, 290-291
 clinical trials of, 281, 293t
 drawbacks of, 281, 286
- Pacing. See also *Pacer-defibrillator, biventricular*.
 atrial, 109t, 165, 167, 272, 274t-275t
 clinical trials of, 274t-275t
 β -blockers and, 199
 biventricular, 258t
 clinical trials on, 262t-265t
 controversies in, 258t
 device insertion in, 261
 failure to consider, 157t
 ventricular, indications for, 153, 159, 257, 259, 260-261, 266
- Pancreatitis, 170t
- Parenteral drug therapy, in decompensation
 advantages and disadvantages of, 238, 239t
 agent adverse effects in, 244t
 chronic/intermittent, 252t
 hemodynamic effects of, 242t-243t
- Passive tension, myocytic, in remodeled heart, 19
- Patent ductus arteriosus, 42
- PATH-CHF, 262t, 324
- Pathophysiology of heart failure, 41-64
 with normal systolic ventricular function vs depressed left ventricular ejection fraction, 87
- Patient education, 141-143, 142t
 dietary, 140
 on hypotension, 219
 on medication schedules, 221
 on nonpharmacologic therapies, 315, 318t
- Penbutolol, 196t
- Pericardiectomy, 252t
- Peripartum cardiomyopathy, 33t, 36
 heart failure treatment in, 319t
- Peripheral edema, 20
 in acute vs chronic heart failure, 22t
- Peripheral vascular disease
 exercise intolerance in, 90t
 management of, 155t
- Persantine stress echocardiography, 82
- Pharmacologic treatment of heart failure. See also specific drugs and drug types.
 administration timing in, 138
 algorithm for, 162-165
 brain natriuretic peptide guidance of, 213, 214t, 217, 219-220
 congestive with low ejection fraction, 168
 drug combinations in, 136t
 classification in, 213, 217
 clinical trials of, 213, 215, 216
 for comorbidities, 213, 215, 219
 compliance and, 217, 221
 effectiveness of, 215
 indications for, 218t
 order of, 166
 selection considerations in, 217
- Pharmacologic treatment of heart failure (*continued*)
 drugs with adverse effects in, 134, 136
 evidence-based, 137-139
 general principles of, 135t-136t
 parenteral, 237-238, 239t-240t, 242t-244t
 scheduling doses of, 217, 221
- Phenytoin (Dilantin), 80t, 212
- Pheochromocytoma, 32t, 35
- Phosphodiesterase inhibitors
 clinical trials of, 106t, 111t-112t, 127
 hemodynamic effects of, 243t
 indications for, 235t
- Physical deconditioning, exercise intolerance in, 90t
- Physical examination, 68, 72, 73t, 74
 in systolic vs diastolic dysfunction, 91t
- PIAF, 96t, 111t, 324
- PICO, 98t, 111t, 127, 129
- Pimobendan, 98t, 111t, 127, 129. See also *PICO*.
- Pindolol, 192, 196t
- Pioglitazone (Actose), 134, 135t, 157t, 217, 230t
- PIPAF, 274t, 324
- Pleural effusion, 225
- Pneumonia
 untreated, 156t
 vaccination against, 154
 in COPD, 155t
- Polyarthritis nodosa, 32t, 35
- Polypharmacy. See *Pharmacologic treatment of heart failure, drug combinations in*.
- Positron emission tomography (PET), 148t
- Potassium metabolism disturbances, 32t
- Potassium supplementation
 dosage of, 178t
 in loop diuretic therapy, 169, 175t
 in volume overload therapy, 173-174
- Potassium-sparing diuretics, 159, 169, 171t, 176t, 190t. See also *Diuretics; specific drugs*.
- PRAISE, 97t, 111t-112t, 126, 324. See also *Amlodipine, clinical trials of*.
- Prazosin (Minipress), 117t, 206t
- PRECEDENT trial, 231
- PRECISE, 97t, 112t
- PRECISE/MOCHA, 112t, 324. See also *Carvedilol, clinical trials of*.
- Prednisone, 110t
- Pregnancy, cardiomyopathy in, 33t, 36
- Preload, definition of, 53, 55
- PRIME-II, 98t, 105t, 112t, 127, 324. See also *Ibopamine*.
- Prinivil. See *Lisinopril*.
- Procainamide (Procanbid and others), 80t, 271t
- PROFILE, 98t, 112t-113t, 127, 324. See also *Flosequinan, clinical trials of*.
- PROMISE, 98t, 112t, 119, 127, 324. See also *Milrinone, clinical trials of*.
- Propafenone (Rythmol), 103t, 267, 271t, 282t
- Propoxyphene (Darvon, Wygesic), 212
- Propranolol, 192-193, 196t
- Prostacyclin, 42, 98t, 107t
- Prostaglandin(s)
 renal effects of, 58t, 60, 61
 as vasodilator, 53, 54
- Protein production, myocytic
 heritable disorders and, 29-30, 31t, 33t
 in hypertrophic cardiomyopathy, 30
 in myocardial injury, 46t
- Proteinuria, 80t, 81
- Prothrombin time, 80t
- PROVED, 98t, 113t, 120, 213, 3324. See also *Digoxin, clinical trials of*.
- Pulmonary abnormalities, 90t
- Pulmonary artery catheterization, 98t, 106t, 323
- Pulmonary artery pressure, in decompensation, 240t
- Pulmonary capillary wedge pressure, in decompensated heart failure, 226t, 227
- Pulmonary congestion, 74
- Pulmonary disease, chronic. See *Chronic obstructive pulmonary disease*.
- Pulmonary edema
 in acute vs chronic heart failure, 22t, 232t
 cardiogenic, management of, 247, 250, 250t

- Pulmonary edema (*continued*)
 in decompensation, 234t
 flash, 20, 144, 299t
 hemodynamic patterns in, 240t
 in low cardiac output, 25t
- Pulmonary embolism
 acute, 37t
 decompensated heart failure and, 229, 230t
 hemodynamic patterns in, 240t
 in low cardiac output, 25t
 in sudden cardiac death, 151
- Pulmonary examination, in heart failure diagnosis, 72, 73t, 74
- Pulmonary system, in heart failure diagnosis, 70t
- Pulmonary vascular resistance, in parenteral drug therapy, 242t-243t
- Pulse pressure, 72
- Pulse rate, self-monitoring of, 141
- Pump dysfunction, in heart failure syndrome, 17, 19
- Pump inadequacy, treatment of, 17, 18t
- Q wave, 82, 83t
 β -blockers and, 191
- QRS duration, 83t, 84
 in pacemaker decisions. See *COMPANION*; *MIRACLE*.
 prolongation of, 257, 259, 260
- QT interval, sotalol and, 268
- Questran (cholestyramine), 212
- Quinapril (Accupril), 188t
- Quinidine (Quinidex), 80t, 271t
- Race, and death from heart failure, 143, 144
- RADIANCE, 98t, 113t, 120, 213, 324. See also *Digoxin, clinical trials of*.
- Radiionuclide imaging, cardiac, 320t
- Radiionuclide ventriculography, 85t
- Rales (pulmonary), 72, 74, 225
- RALES (study), 98t, 113t, 119, 127, 183, 3324
 spironolactone on, 183
- Ramipril (Altace)
 adverse effects of, 188t
 clinical trials of, 96t-97t, 99, 100t-101t, 107t, 109t, 186-187, 321. See also *AIRE*; *AIREX*.
 in diabetics, 109t
 dosage of, 188t
 effectiveness of, 99
- Rare diseases, heart failure treatment in, 319t
- Reactive airway disease
 management of, 219
 metoprolol and, 191
- REFLECT, 98t, 113t, 324
- Refractory heart failure, 250-251, 252t
- Refsum's syndrome, 32t
- Regurgitation. See *Mitral valve regurgitation*.
- REMATCH, 113t, 297, 324
- Remodeling, 19
 components of, 48-49
 drug prevention of, 217
 exercise and, 106t
 in muscular dystrophy, 45
 myocyte protein production and, 30
 passive tension and workload in, 19
 pathophysiology of, 62, 64, 64t
 surgical, 19, 159
 Batista procedure in, 252t, 300-301
 law of Laplace in, 300, 301
 in volume overload, 50
- RENAISSANCE, 98t, 113t, 324
- Renal dysfunction
 ACE inhibitors and, 186-187, 188t-189t, 221, 224
 decompensated heart failure and, 230t
 drug selection in, 167-168
 management of, algorithm for, 221, 224
 NSAIDs and, 190t, 136121
 sotalol in, 268
- Renal system, in heart failure diagnosis, 70t
- Renin
 cardiac output and, 52
 ejection fraction and, 56, 57
- Renin-angiotensin-aldosterone system
 in acute vs chronic heart failure, 23t, 233t
 in arrhythmia, 151
 systemic and tissue, 59-60
- RESOLVD, 96t, 114t, 324-325. See also *β -Blockers, clinical trials of*.
- Respirations, periodic, 234t
- Restrictive cardiomyopathy, 31t
- Revascularization, 252t
 ACE inhibitors after, 101t
 for angina, 144, 164, 167
 clinical trials of, 98t, 115t
 contraindications to, 144
 indications for, 146-147, 149
 for refractory heart failure, 250-251, 252t
 for ventricular tachycardia, indications for, 288
- Rheumatoid arthritis, 32t, 35
- Rifadin (rifampin), 212
- Rifampin (Rifadin), 212
- Right heart failure, sleep apnea and, 71
- RITZ, 98t, 114t, 325. See also *Tezoseptan, clinical trials of*.
- Rosiglitazone (Avandia)
 adverse effects of, 134, 157, 216-217, 230t
 discontinuation of, 135t
- Rythmol (propafenone), 103t, 267, 271t, 282t
- Salt-restricted diet, 139, 140, 142, 156t
 in ACC/AHA heart failure management guidelines, 65
 in decompensation, 231, 235t
 diuretics and, 168-169
- Sandimmune (cyclosporine), 110t, 212
- Sarcoidosis, 32t, 35
- Sarcomeres
 composition of, 41
 myocardial mass and, 49
 parallel and series, 51
 pressure overload and, 49
- SAVE, 95, 96t, 99, 100t, 114t, 119, 186, 325
- SCD-HeFT, 97t, 100t, 114t, 200, 280, 284t, 325. See also *Death from heart failure, sudden*.
- Scintigraphy, 82
- Scleroderma, 32t, 35
- Selenium deficiency, 32t, 35
- Self-monitoring techniques, 141
- Sexual activity, 142t, 143
- Shock
 cardiogenic
 intra-aortic balloon counterpulsation for, 238
 in low cardiac output, 25t
 hemodynamic patterns in, 240t
- SHOCK study, 98y, 115t, 3325
- Sick sinus syndrome, 272
- Signaling receptor density, 45, 48
- Sildenafil (Viagra), 142t, 143
- Sleep apnea, 154, 219
 in COPD, 155t
 in decompensated heart failure, 225, 226t, 230t
 management of, 218t, 219
 right heart failure and, 71
- SMILE, 95, 96t, 99, 100t, 115, 187, 325. See also *Myocardial infarction, survival of*.
- Smoking
 comorbid conditions and, 154
 in COPD, 155t
 heart failure treatment and, 65, 156t
- Snake venom, 61t
- SOLVD, 56, 62, 95, 96t, 115t, 119, 126, 325
 ACE inhibitor effectiveness on, 184-185
 drug combinations in, 213, 215, 216
 findings of, 57, 99, 138-139
 neurohormones and ejection fraction in, 56, 57
 sudden cardiac death incidence on, 150t
 tumor necrosis factor in, 62, 63

- Sorbitrate. See *Isosorbide dinitrate*.
- Sotalol (Betapace)
 adverse effects of, 268
 for atrial fibrillation, 270, 271t
 β-blocker effects of, 268
 clinical trials of, 96t, 101t, 116t, 123, 325
 contraindications to, 268
 features of, 192-193, 196t
 QT interval monitoring in, 268
 safety of, 268
- SPICE, 96t, 115t, 215, 216, 325
- Spironolactone (Aldactone). See also *Aldosterone antagonists*.
 adverse effects of, 177, 177t, 182, 183
 algorithm for, 177, 180-181, 183
 clinical trials of, 98t, 113t, 119, 127, 324
 dosage of, 181-182, 183
 indications for, 180-181
- Stages of heart failure, 21, 24
- Starvation, 32t, 35
- Statins, 218t
- Stenosis, idiopathic hypertrophic subaortic, 31t, 33-34
- Streptokinase, 103t
- Stress echocardiography, with dobutamine, 82, 145, 297
- Stretch receptors, 50
- STRETCH study, 96t, 115, 325. See also *Candesartan, clinical trials of*.
- Stroke
 in cardioversion, 266
 in sudden cardiac death, 151
- Studies of heart failure, Framingham, 26, 28
- Sucralfate (Carafate), 212
- Sudden cardiac death. See *Death from heart failure, sudden*.
- Sulfapyrazone (Anturane), 212
- SUPPORT, 98t, 116t, 325
- Surgical treatments
 Acorn cardiac support as, 297, 306
 clinical trials of, 98t. See also *CASS*.
 evidence-based, 296t
 imaging for, 84
 indications for, 18t, 156t, 252t, 295
 infarct exclusion as, 301, 302-303, 304, 305t
 mechanical assist devices in, 296-297
 Myosplint as, 297-307-308, 304, 306
 new, emerging, and experimental, 296t
 remodeling as, 19, 159, 300-301, 301
- SWORD, 96t, 116t, 123, 325
- Sympathetic nervous system
 in acute vs chronic heart failure, 22t, 232t
 cardiac output and, 52
- Sympathomimetics, parenteral, hemodynamic effects of, 242t
- Symptoms of heart failure, 17, 19-21
- Systemic illness, in heart failure diagnosis, 73t, 74
- Systemic lupus erythematosus, 32t, 35
- Systole, myofilaments in, 41
- Systolic dysfunction
 diagnosis of, 91t
 without dilation, 31t
 in heart failure, 41
 acute vs chronic, 232t
 remodeling in, 64t
- Systolic wall stress. See also *Wall stress*.
 in volume overload, 50
- Tachycardia
 clinical studies of, 110t
 drug-induced, 244t
 idiopathic right ventricular outflow tract, 31t
 left ventricular dysfunction and, 266
 resting, 72, 225, 226t
 supraventricular, 42
 ventricular
 management of, 287-289
 pacemakers for. See *COMPANION; MIRACLE* entries.
- Tachycardia, ventricular (*continued*)
 prognosis and, 143
 in sudden cardiac death, 151, 151t, 152
- Tachyphylaxis, 249t
- Tachypnea, 72
 in decompensation, 234t
 resting, 225
- Tagamet (cimetidine), 212
- Talinolol, 196t
- Tambacor (flecainide), 103t, 123, 267, 271t
- Tamoxifen (Nolvadex), 212
- Tamponade
 hemodynamic patterns in, 240t
 in low cardiac output, 25t
 from pericardial effusion, 37t
- Tegison (etretinate), 212
- Tegretol (carbamazepine), 212
- Telmisartan (Micardis), 206t
- Tenex (guanfacine), 207t
- Terazosin (Hytrin), 206t
- Tetracycline (Achromycin V), 212
- Tezosentan
 clinical trials of, 98t, 114t. See also *RITZ*.
 hemodynamic effects of, 243t
- Thallium scintigraphic studies, 82
- Thiazide diuretic trials, 100t, 169, 171t, 177, 218t
- Thiazolidinediones
 adverse effects of, 135t, 154, 157t, 217, 218t, 230t
 in diabetes, 155t, 320t
- Thiocyanate toxicity, 244t
- Thoracic impedance, 226t
- Thrombocytopenia, 79, 244t
- Thrombolysis trials, 103t. See also *CATS*.
- Thrombophlebitis, 208
- Thrombosis, in acute vs chronic heart failure, 23t
- Thromboxane, 54
- Thyroid dysfunction
 decompensated heart failure and, 230t
 unrecognized, 156t
- Thyroid function tests, 80t, 81
- Thyrotoxicosis, 32t, 35, 42
- Tikosyn (dofetilide), 96t, 105t, 124, 271t, 322
- Timolol, 192-193, 196t
- Tissue, renin-angiotensin system in, 59
- Toprol. See *Metoprolol succinate CR/XL*.
- Torsade de pointes
 antiarrhythmics and, 124
 in sudden cardiac death, 149, 151, 151t
- Torsemide (Demadex), 170t, 176, 177t
- TRACE, 95, 96t, 99, 100t, 116t, 187, 325. See also *Trandolapril, clinical trials of*.
- Trandolapril (Mavik)
 adverse effects of, 188t
 clinical trials of, 96t, 99, 116t. See also *TRACE*.
 dosage of, 188t
 effectiveness of, 99
 mortality end points with, 187
- Transesophageal echocardiography, 266-267, 270
- Transplantation of heart. See *Cardiac transplantation*.
- Travel altitude, 229, 230t
- Trazodone (Desyrel), 212
- Treatment of heart failure. See also *Pharmacologic treatment of heart failure; Surgical treatments*.
 in coronary artery disease, 143-145, 148-149
 decision tree for, 146-147
 electrophysiologic, 149, 151, 153, 153t
 general principles in, 135t-136t
 guidelines for
 common themes in, 314-315, 318t
 limitations of, 313, 315
 nonpharmacologic, 136t, 139-140, 315, 318t. See also specific therapy, eg, *Exercise*.
 Triamterene (Maxzide), 171t
 Tricuspid insufficiency, 225

Tricyclic antidepressants, 136
Tropomyosin functions, 41
Troponin functions, 30, 41
Troponin protein production, 30, 33t
Tumor necrosis factor
 in heart failure, 62, 63
 modulators of, 113t
Two-dimensional echocardiography, 83t, 84, 85t

Unipen (nafcillin), 212
United States Department of Health and Human Services Agency for Health Care Policy
 and Research, heart failure treatment guidelines of, 314, 316t
Univasc (moexipril), 186, 188t
Urinalysis, 80t

V wave, 226t
Vaccination
 in COPD, 155t
 against flu and pneumonia, 154
 warfarin interaction with, 212
Val-HeFT, 96t, 116t, 119, 325. See also *Valsartan, clinical trials of*.
VALIANT, 96t, 116t, 125, 325. See also *Valsartan, clinical trials of*.
Valsalva's maneuver, 226t, 227
Valsartan (Diovan)
 adverse effects of, 202t, 206t
 clinical trials of, 96t, 116t, 119, 125. See also *Val-HeFT; VALIANT*.
 dosage of, 202t, 206t
 effectiveness of, 137, 199, 203
 indications for, 162-163, 166, 189, 199
Valves. See *Aortic valve* entries; *Mitral valve* entries.
Valvular disease, ACC/AHA heart failure management guidelines in, 65
Valvular obstruction/insufficiency, 31t, 34
Vascular resistance
 in decompensation, 240t
 neurohormones in, 57-58, 60
 in parenteral drug therapy, 242t-243t
Vasoactive drugs, daily protocol for, 219-220, 220t
Vasoconstriction
 in decompensated heart failure, 225, 226t
 drugs for, 54
 excessive, 244t
 in hemodynamic monitoring, 236-238, 238t-239t, 248t-249t
Vasodilators. See also specific drugs.
 adverse effects of, 152, 190t, 207t
 blood flow and, 54
 in blood flow autoregulation, 54
 clinical trials of, 93-94, 98t, 104t, 113t, 115t, 117t, 119, 150t, 185t, 325
 in combination therapy, 95, 127, 218t, 236
 for decompensation, 234, 235t, 236, 248t-249t
 dosage of, 162-163, 189, 199, 201t, 207t, 221, 248t-249t
 inadequate, 156t
 effectiveness of, 234
 hemodynamic effects of, 242t
 for hypertension, 164
 for hypotension, 157
 indications for, 17, 18t, 19, 159, 164, 166, 180, 235t
 mortality and, 94, 104t, 127
 neurohumoral release and, 52, 53
 parenteral, 237, 242t, 244t
 for pulmonary edema, 247, 250t
 renal effects of, 58, 58, 167
 for volume overload, 162, 164, 166-167
Vasopressin. See *Arginine vasopressin*.
Vasotec. See *Enalapril*.
Vaughan-Williams classification, 103t, 267
Vector, 264t
Ventak-CHF, 293t
Ventilation/perfusion, exercise intolerance in, 90t
Ventricle
 left. See also *Left ventricular* entries.
 fibrosis and remodeling of, aldosterone and, 57
 isolated systolic without chamber dilation, 34
 right
 arrhythmic, 31t, 34
 idiopathic outflow tract tachycardia of, 31t
 Ventricular arrhythmia, 31t, 34, 286t. See also *Pacer-defibrillator, biventricular*.
 in decompensated heart failure, 226t, 227
 electrophysiologic study of, indications for, 281, 286t
 malignant, 34, 123
 prevention of, 280-281
 sudden death and, 151, 151t, 152, 273, 280
 undiagnosed/untreated, 157t
 Ventricular assist devices, 251. See *Cardioversion defibrillators, implanted; Pacer-defibrillator, biventricular; Pacing*.
 in ACC/AHA heart failure management guidelines, 65
 clinical trials of, 113t, 324
 indications for, 159
 Ventricular cardiomyopathy, arrhythmogenic right, 31t, 34
 Ventricular dysfunction
 ACE inhibitors for, 166
 in acute vs chronic heart failure, 22t
 asymptomatic, 20
 carvedilol and, 102t
 in heart failure, 41
 hypertension management in, 219
 in low cardiac output, 25t
 tachycardia and, 266
 Ventricular enlargement, survival and, 114t, 119. See also *SAVE*.
 Ventricular failure, right, hemodynamic patterns in, 240t
 Ventricular hypertrophy
 cardiac decompensation and, 17, 18t
 in myocardial remodeling, 19
 treatment of, 18t
 Ventricular remodeling, 50. See also *Remodeling*.
 Ventricular scar, 304
 Ventricular septum
 defect in, 50
 ruptured, 37t
 Ventricular systolic function
 ACE inhibitors and, 166, 179
 in acute vs chronic heart failure, 232t
 Ventricular tachycardia. See *Tachycardia, ventricular*.
 nonsustained, management after, 287-289
Verapamil
 for atrial fibrillation, 269, 271t
 atrial-ventricular node conduction and, 269
 bradycardia and, 199, 201t
Vesnarinone, 98t, 117t, 119, 127, 129, 325
VEST, 98t, 117t, 119, 127, 325
V-HeFT-I, 93-94, 98t, 137, 150t, 201, 213, 325
V-HeFT-II, 95, 96t, 150t, 185
V-HeFT-III, 97t, 117t, 126
Viagra (sildenafil), 142t, 143
Vital signs, in heart failure diagnosis, 72, 73t
Vitamin B₆ deficiency, 35
Vitamin E, 107t
Vitamin K, 210-212
VMAC, 98t, 117t, 231, 241, 245t, 325. See also *Vasodilators, clinical trials of*.
Volume depletion. See also *Filling pressure*.
 diuretics for, 169, 172-174
 hypotension and, 165, 167-168
 as pitfall, 156t-157t, 164
 Volume overload, 41. See also *Decompensated heart failure; Filling pressure*.
 blood pressure and, 166
 causes of, 42, 46t
 drug selection in, 161, 162-164, 166, 173
 responses to, 50-51, 448-49
 signs of, 225, 226t
 Volume reduction surgery, Batista procedure in, 252t, 300-301
 Volume status assessment, 72, 74

Wall rupture, 37t
Wall stress
 in acute vs chronic heart failure, 22t, 232t
 in hypertrophic cardiomyopathy, 30, 33
 inflammation and, 62
 systolic, in volume overload, 162
 in volume overload, 50
Warfarin. See also *Anticoagulants*.
 after cardioversion, 270
 before cardioversion, 266, 270
 clinical trials of, 98t, 117t, 216t, 325
 controversy over, 136-137
 dosage of, 211
 drug interactions with, 208, 212
 indications for, 205, 207, 209-210, 266
 patient self-monitoring in, 208
WATCH, 117t, 325, 998t
Water restriction. See *Fluid restriction*.
Weber-Janicki exercise test, 86, 88-89
Weight, self-monitoring of, 141
Weight gain
 in acute vs chronic heart failure, 22t, 232t
 oral hypoglycemic agents and, 134
Workload, in remodeled heart, 19
World Health Organization (WHO)
 classification of heart failure by, 30, 31t-33t, 33, 36
 heart failure treatment guidelines of, 316t
Wygesic (propoxyphene), 212

Xamoterol
 clinical trials of, 98t, 109t, 117t, 127, 325. See also *MEXIS*.
 features of, 196t

Zaroxolyn (metolazone), 212
Zebeta. See *Bisoprolol*.
Zestril. See *Lisinopril*.
Zofenopril
 clinical trials of, 96t, 115t, 187
 effectiveness of, 99, 187